These findings emphasize the clinical relevance of EGFR and BRAF kinase domain duplications in NSCLC and highlight the potential of targeted therapies tailored to these recurrent molecular alterations (25–27), the impact of varying TD lengths on tumor progression is yet to be fully understood. This evidence concerns the gene EGFR and non-small cell lung carcinoma.